What is Biorithm?
Biorithm is a forward-thinking medical technology start-up dedicated to enhancing maternal healthcare. Its core offering, the femom platform, is a sophisticated obstetric remote monitoring system. This comprehensive solution aims to elevate the care journey for expectant mothers by equipping clinicians with superior insights and fostering greater patient engagement. The femom platform integrates a clinical-grade fetal-maternal monitor with connected devices, facilitating continuous oversight and enabling data-informed clinical decisions. Biorithm's strategic focus is on addressing the unique needs of individual patients while championing safety, patient choice, and accessibility within women's health.
How much funding has Biorithm raised?
Biorithm has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2023): $3.5M with participation from Seeds Capital
Key Investors in Biorithm
Seeds Capital
Seeds Capital is an investment entity that appears to focus on the Electricity, Oil & Gas sectors, indicating a potential diversification strategy or a broad investment mandate that includes innovative health technology.
What's next for Biorithm?
With this significant strategic investment, Biorithm is poised for accelerated growth and product development. The company is expected to leverage this capital to expand its market reach, further enhance the capabilities of its femom platform, and potentially explore new applications in digital health for women's wellness. The enterprise-level backing suggests a strategic vision for scaling operations and solidifying its position as a leader in remote maternal monitoring solutions, aiming to make advanced healthcare insights more accessible to a broader patient demographic.
See full Biorithm company page
